Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients

摘要: Aromatase inhibitors represent an effective endocrine treatment for patients with hormone receptor-positive breast cancer, in early stage and metastatic disease. However, by decreasing levels of serum estrogens they also potentially reduce the protective effect on cardiovascular system. Patients treated aromatase inhibitors, fact, compared those who receive tamoxifen, more often develop hyperlipidemia, hypercholesterolemia, hypertension, which are recognized risk factors This might raise some concerns especially adjuvant setting where aim is cure, postmenopausal already at whether relative higher incidence cardiac adverse events reported tamoxifen related to actual toxicity rather than a cardioprotective still unclear. In this article we review available literature cardiotoxicity provide practical advice improve safety profile these drugs.